실시간
FierceBiotechChutes & Ladders—AstraZeneca adds FDA cell and gene veteranLabiotechEight oncology deals in 2026 spotlight where industry leaders are betting bigEndpoints NewsFulcrum lays off majority of staff; Seres extends runway into 2027PharmaVoiceGSK, Takeda and others notch key clinical wins in tough-to-treat diseasesFierceBiotechHow RA Capital is offering its biotechs ‘Chinese clinical expertise in a box’Endpoints NewsNovo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial execBioPharma DivePharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?Lonza NewsStipple Bio taps Lonza platform to advance ADC pipeline - The Pharma LetterCellSingle-cell mapping of regulatory DNA-protein interactionsCellPlasma signals of lung tumor promotion for molecular cancer preventionCellDeep learning of functional perturbations from condensate morphologyFierceBiotechAt first public hearing for FDA’s CNPV program, industry support meets ‘deep concern’ from experts
PharmaVoice 2026년 1월 16일

The clinical candidates pharma execs are tracking

The clinical candidates pharma execs are tracking

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.